According to the Huatai Securities Research Report, on July 9, the National Health and Health Commission issued the “National Essential Drug Catalogue”, and the new version of the catalogue will be implemented on September 1. According to the National Health Commission, this adjustment is the first comprehensive update since the 2018 edition of the catalogue. A total of 794 drugs have been included, and 116 new varieties have been added. For the first time in this catalogue, innovative drugs are used as the selection direction in the selection mechanism, and 4 new domestically produced first-class innovative drugs have been included. Huatai Securities believes that the innovative drug support policy is being extended from review and approval, medical insurance admission to basic drug catalogues, grass-roots preparation, standardized use, and drug use links between higher and lower levels of medical institutions. It is expected to enhance the clinical accessibility of domestically produced innovative drugs and continue the policy orientation since the “Implementation Plan to Support the Development of Innovative Drugs in a Full Chain”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.